In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. David Viveros-Carreño and Rene Pareja to discuss Sedlis criteria. Dr. Viveros-Carreño is a Gynecologic Oncologist at Instituto Nacional de Cancerología, Clínica Universitaria Colombia and Clínica Los Nogales in Bogotá, Colombia. Dr. Pareja is a gynecologist oncologist at Astorga Oncology Clinic in Medellín and the National Cancer Institute in Bogotá, Colombia. Dr. Pareja is a reviewer for more than 20 specialty journals, an Associate Editor for IJGC, and a member of the board of directors of the International Gynecological Cancer Society (IGCS). He is the author of nine book chapters and more than 70 publications in peer-reviewed journals, and at IGCS 2021 he received an award for Community Advancement in Resource-Limited Settings.



Highlights:

-There is currently a debate regarding the role of adjuvant therapy for intermediate-risk cervical cancer.
-Adjuvant pelvic radiotherapy showed lower risk of recurrence for intermediate-risk cervical cancer in a randomized controlled trial more than 20 years ago.
-Preoperative imaging, surgery, pathology, and radiotherapy techniques have changed since the evidence for intermediate risk adjuvant treatments was described.
-The risk of recurrence for intermediate risk cervical cancer is probably lower now, and observation could be an option.
-New evidence from two randomized controlled trials (GOG 263 and CERVANTES trials) is expected to change definitions of intermediate risk and adjuvant algorithms.